Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall short

Main PageFebruary 6, 2025

Zepbound and Mounjaro have now underperformed expectations for two straight quarters.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent